Syapse to Work With Predictive Safety Testing Consortium Working Group

PALO ALTO, Calif.--(BUSINESS WIRE)--Syapse announced today that the Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) Cardiac Hypertrophy Working Group has agreed to participate in a pilot program that will use Syapse’s cloud-based, Biomedical Development Management (BDM) software to help facilitate scientific collaboration and decision making by members of the working group.

“We are honored that PSTC has agreed to utilize Syapse’s technology to support their global efforts, said Matthew Cooper, Chief Science Officer and Vice President, Business Development of Syapse.”

The working group will initially use Syapse BDM to record and share experimental results of the safety biomarkers under assessment. Using only a web browser, members will be able to coordinate research plans and enter experimental results into Syapse BDM from the sites of their individual laboratories. Meeting via teleconferences, they will easily be able to see and assess results and make evidence-based decisions to move their research forward.

The PSTC is a unique public – private partnership that includes 17 biopharmaceutical companies, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the National Institute of Health (NIH). The PSTC's objective is to improve drug safety by developing standards for the qualification of biomarkers submitted for regulatory approval. PSTC members share internal research and experience about non-clinical and clinical safety biomarkers with a strong translational focus. The consortium currently has six active working groups, including the Cardiac Hypertrophy Working Group.

"We are excited about working with Syapse to help PSTC’s Cardiac Hypertrophy Working Group collaborate and review data to make decisions more effectively," said Dr. Eslie Dennis, Executive Director of the PSTC. "Our membership is global in scope, and we expect Syapse to make it easy for them to enter, access, compare, and assess results from their investigations of safety biomarkers."

Syapse BDM is a cloud-based application suite that enables companies to accelerate biomedical product development by:

Organizing and communicating biological results and findings
Tracking and reporting progress towards meeting scientific milestones and deliverables
Summarizing the most important project results and evidence for decision-making
Sharing information with internal and external collaborators

"We are honored that PSTC has agreed to utilize Syapse’s technology to support their global efforts, said Matthew Cooper, Chief Science Officer and Vice President, Business Development of Syapse. "We look forward to working closely with the working group members to support their efforts in advancing safety biomarkers."

About Syapse: Syapse Inc. develops software applications to accelerate biology-based research and product development. Spun out of Stanford University and led by an experienced, multidisciplinary team of entrepreneurs, software developers, and scientists, Syapse's applications enable faster, more informed weight-of-evidence decisions using biological information. Built on top of our proprietary BioSemantic Platform, Syapse applications deliver value to organizations of all sizes, from the individual scientist and small academic laboratories, to emerging biotechnology companies, to large molecular diagnostics and pharmaceutical companies. For more information, please see www.Syapse.com

About Critical Path Institute (C-Path): An independent, non-profit organization established in 2005 with public and private philanthropic support from the Southern Arizona community, Science Foundation Arizona (SFAz), and the U.S. Food and Drug Administration (FDA), C-Path is committed to improving health and saving lives by accelerating the development of safe, effective medicines. An international leader in forming collaborations around this mission, C-Path has established global, public-private partnerships that currently include over 1,000 scientists from government regulatory agencies, academia, patient advocacy organizations, and thirty five major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona, with offices in Phoenix, Arizona, and Rockville, Maryland. For more information, visit www.c-path.org.